Ra Capital Management, L.P. 13F annual report
Ra Capital Management, L.P. is an investment fund managing more than $7.56 trillion ran by Rajeev Shah. There are currently 78 companies in Mr. Shah’s portfolio. The largest investments include Ascendis Pharma A/s - Adr and Vaxcyte, together worth $2 trillion.
$7.56 trillion Assets Under Management (AUM)
As of 7th August 2024, Ra Capital Management, L.P.’s top holding is 10,108,400 shares of Ascendis Pharma A/s - Adr currently worth over $1.38 trillion and making up 18.2% of the portfolio value.
In addition, the fund holds 8,203,754 shares of Vaxcyte worth $619 billion, whose value grew 3.5% in the past six months.
The third-largest holding is Janux Therapeutics Inc worth $384 billion and the next is Legend Biotech Corp-adr worth $332 billion, with 7,506,934 shares owned.
Currently, Ra Capital Management, L.P.'s portfolio is worth at least $7.56 trillion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
Careers at Ra Capital Management, L.P.
The Ra Capital Management, L.P. office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Rajeev Shah serves as the Authorized Signatory at Ra Capital Management, L.P..
Recent trades
In the most recent 13F filing, Ra Capital Management, L.P. revealed that it had opened a new position in
Recursion Pharmaceuticals-a and bought 15,384,615 shares worth $115 billion.
The investment fund also strengthened its position in Legend Biotech Corp-adr by buying
645,837 additional shares.
This makes their stake in Legend Biotech Corp-adr total 7,506,934 shares worth $332 billion.
On the other hand, there are companies that Ra Capital Management, L.P. is getting rid of from its portfolio.
Ra Capital Management, L.P. closed its position in Inhibrx on 14th August 2024.
It sold the previously owned 2,629,837 shares for $91.9 billion.
Rajeev Shah also disclosed a decreased stake in Apogee Therapeutics Inc by approximately 0.1%.
This leaves the value of the investment at $77.2 billion and 1,961,863 shares.
One of the largest hedge funds
The two most similar investment funds to Ra Capital Management, L.P. are Tortoise Capital Advisors, L.L.C and Synovus Financial Corp. They manage $7.56 trillion and $7.55 trillion respectively.
Rajeev Shah investment strategy
Ra Capital Management, L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 33.0% of
the total portfolio value.
The fund focuses on investments in the United States as
30.8% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
3% of the total holdings value.
On the other hand, large-cap stocks make up only 1.3% of the portfolio.
The average market cap of the portfolio companies is close to $2.52 billion.
The complete list of Ra Capital Management, L.P. trades based on 13F SEC filings
These positions were updated on August 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Ascendis Pharma A/s - Adr |
No change
10,108,400
|
$1,378,583,592,000 | 18.23% |
| Vaxcyte, Inc. |
No change
8,203,754
|
$619,465,465,000 | 8.19% |
| Janux Therapeutics Inc |
No change
9,165,652
|
$383,949,162,000 | 5.08% |
| Legend Biotech Corp-adr |
9.41%
7,506,934
|
$332,482,107,000 | 4.40% |
| Rhythm Pharmaceuticals Inc. |
14.15%
6,084,412
|
$249,825,957,000 | 3.30% |
| Biogen Inc |
32.59%
982,139
|
$227,679,463,000 | 3.01% |
| Eliem Therapeutics Inc |
138.91%
31,419,267
|
$223,390,988,000 | 2.95% |
| Rxsight Inc |
7.32%
3,694,825
|
$222,317,620,000 | 2.94% |
| Avidity Biosciences, Inc. |
64.54%
5,400,408
|
$220,606,667,000 | 2.92% |
| Dyne Therapeutics, Inc. |
22.09%
6,049,204
|
$213,476,409,000 | 2.82% |
| Geron Corp. |
No change
46,202,425
|
$195,898,282,000 | 2.59% |
| Pepgen Inc |
No change
10,689,545
|
$170,605,138,000 | 2.26% |
| Tyra Biosciences Inc |
No change
10,416,609
|
$166,561,578,000 | 2.20% |
| Evolent Health Inc - A |
48.44%
8,514,862
|
$162,804,161,000 | 2.15% |
| Edgewise Therapeutics Inc |
No change
8,909,091
|
$160,452,729,000 | 2.12% |
| Newamsterdam Pharma Co Nv |
2.54%
8,064,000
|
$154,909,440,000 | 2.05% |
| Recursion Pharmaceuticals-a |
Opened
15,384,615
|
$115,384,613,000 | 1.53% |
| 89bio Inc |
11.03%
14,175,398
|
$113,544,938,000 | 1.50% |
| Verona Pharma Plc - Adr |
20.81%
7,632,646
|
$110,368,061,000 | 1.46% |
| Day One Biopharmaceuticals I |
0.79%
7,871,721
|
$108,472,315,000 | 1.43% |
| 4d Molecular Therapeutics In |
0.92%
5,098,211
|
$107,011,449,000 | 1.42% |
| Ars Pharmaceuticals Inc |
No change
10,860,977
|
$92,426,914,000 | 1.22% |
| Inhibrx, Inc. |
Closed
2,629,837
|
$91,939,102,000 | |
| Wave Life Sciences Ltd. |
No change
18,202,009
|
$90,828,025,000 | 1.20% |
| Longboard Pharmaceuticals In |
No change
3,289,119
|
$88,904,887,000 | 1.18% |
| Arcellx Inc |
Opened
1,604,014
|
$88,525,533,000 | 1.17% |
| Axsome Therapeutics Inc |
No change
1,000,000
|
$80,500,000,000 | 1.06% |
| Apogee Therapeutics Inc |
0.81%
1,961,863
|
$77,199,309,000 | 1.02% |
| Gh Research Plc |
5.60%
6,601,689
|
$76,975,694,000 | 1.02% |
| Structure Therapeutics Inc |
25.58%
1,896,772
|
$74,486,236,000 | 0.99% |
| Lenz Therapeutics Inc |
No change
4,178,823
|
$72,251,850,000 | 0.96% |
| Fulcrum Therapeutics Inc |
No change
11,609,704
|
$71,980,165,000 | 0.95% |
| Nkarta, Inc. |
No change
10,805,129
|
$63,858,312,000 | 0.84% |
| Dianthus Therapeutics Inc |
No change
2,333,000
|
$60,378,040,000 | 0.80% |
| Mineralys Therapeutics Inc |
No change
4,850,984
|
$56,756,513,000 | 0.75% |
| Madrigal Pharmaceuticals Inc |
Closed
204,500
|
$54,609,680,000 | |
| iTeos Therapeutics, Inc. |
20.37%
3,517,259
|
$52,196,124,000 | 0.69% |
| UroGen Pharma Ltd |
No change
3,083,430
|
$51,739,955,000 | 0.68% |
| Praxis Precision Medicines I |
49.16%
1,235,599
|
$51,104,375,000 | 0.68% |
| Enliven Therapeutics Inc |
No change
2,122,465
|
$49,602,007,000 | 0.66% |
| Acrivon Therapeutics Inc |
73.38%
8,340,508
|
$48,374,946,000 | 0.64% |
| Astria Therapeutics Inc |
14.29%
5,043,756
|
$45,898,180,000 | 0.61% |
| Cytek Biosciences Inc |
Closed
6,809,404
|
$45,691,101,000 | |
| Bicycle Therapeutics Plc-adr |
181.63%
2,253,000
|
$45,600,720,000 | 0.60% |
| Cg Oncology Inc |
No change
1,397,433
|
$44,116,960,000 | 0.58% |
| Larimar Therapeutics, Inc. |
No change
6,045,351
|
$43,828,795,000 | 0.58% |
| Acumen Pharmaceuticals Inc |
No change
14,932,063
|
$36,135,592,000 | 0.48% |
| Tourmaline Bio Inc |
Opened
2,538,925
|
$32,650,576,000 | 0.43% |
| Third Harmonic Bio Inc |
No change
2,033,056
|
$26,429,728,000 | 0.35% |
| Solid Biosciences Inc |
No change
4,330,446
|
$24,553,629,000 | 0.32% |
| Taysha Gene Therapies, Inc. |
No change
10,872,503
|
$24,354,407,000 | 0.32% |
| Tenaya Therapeutics Inc |
32.45%
7,622,347
|
$23,629,276,000 | 0.31% |
| Vor Biopharma Inc |
No change
22,748,880
|
$22,748,880,000 | 0.30% |
| C4 Therapeutics, Inc. |
No change
4,878,000
|
$22,536,360,000 | 0.30% |
| Alto Neuroscience Inc |
50.53%
2,085,554
|
$22,294,572,000 | 0.29% |
| Immatics Nv |
No change
1,750,000
|
$20,335,000,000 | 0.27% |
| Vaxart Inc |
Closed
15,384,615
|
$20,000,000,000 | |
| EyePoint Pharmaceuticals Inc |
Closed
938,591
|
$19,400,676,000 | |
| Sera Prognostics Inc-a |
49.83%
3,032,808
|
$17,954,223,000 | 0.24% |
| Black Diamond Therapeutics I |
Closed
3,525,754
|
$17,875,573,000 | |
| Aerovate Therapeutics Inc |
11.23%
9,192,092
|
$15,258,873,000 | 0.20% |
| Werewolf Therapeutics Inc |
No change
6,144,881
|
$14,993,510,000 | 0.20% |
| Cervomed Inc |
5.16%
817,120
|
$13,989,094,000 | 0.19% |
| Pliant Therapeutics, Inc. |
No change
1,281,000
|
$13,770,750,000 | 0.18% |
| Nurix Therapeutics, Inc. |
Opened
650,000
|
$13,565,500,000 | 0.18% |
| Insmed Inc |
Opened
200,000
|
$13,400,000,000 | 0.18% |
| An2 Therapeutics Inc |
No change
5,551,295
|
$11,935,284,000 | 0.16% |
| Cybin Inc |
24.31%
44,004,464
|
$11,925,210,000 | 0.16% |
| Zura Bio Ltd |
Opened
3,217,503
|
$11,261,261,000 | 0.15% |
| Arvinas Inc |
No change
421,348
|
$11,216,284,000 | 0.15% |
| Regulus Therapeutics Inc |
No change
6,250,000
|
$11,156,250,000 | 0.15% |
| Lexeo Therapeutics Inc |
1.78%
672,712
|
$10,790,300,000 | 0.14% |
| Adicet Bio Inc |
No change
7,541,000
|
$9,124,610,000 | 0.12% |
| Nuvalent Inc-a |
Opened
119,789
|
$9,087,194,000 | 0.12% |
| IGM Biosciences, Inc. |
Closed
937,500
|
$9,046,875,000 | |
| Macrogenics Inc |
No change
2,082,021
|
$8,848,589,000 | 0.12% |
| Boundless Bio Inc |
No change
2,180,631
|
$8,439,042,000 | 0.11% |
| Chimerix Inc |
No change
8,800,000
|
$7,708,800,000 | 0.10% |
| Perceptive Capital Solutions |
Opened
750,000
|
$7,545,000,000 | 0.10% |
| COMPASS Pathways plc |
Closed
791,359
|
$6,584,107,000 | |
| Metagenomi Inc |
15.29%
1,477,749
|
$6,029,216,000 | 0.08% |
| Curevac Nv |
Closed
1,965,707
|
$5,956,092,000 | |
| Protara Therapeutic Inc |
Opened
1,900,000
|
$3,952,000,000 | 0.05% |
| Surrozen Inc |
Opened
282,580
|
$3,094,251,000 | 0.04% |
| Newamsterdam Pharma Co Nv-27 |
No change
333,333
|
$2,906,664,000 | 0.04% |
| Unicycive Therapeutics Inc |
24.16%
2,632,200
|
$1,318,995,000 | 0.02% |
| Scilex Holding Co |
Opened
261,179
|
$504,075,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 87 holdings | |||
Hedge funds similar to Ra Capital Management, L.P.
- Oppenheimer Asset Management Inc
- Brandes Investment Partners, L.P.
- Fundsmith Investment Services Ltd
- Wealthspire Advisors
- Df Dent & Co Inc
- Atria Investments, Inc
- Greenhaven Associates Inc
- Tortoise Capital Advisors, L.L.C
- Synovus Financial Corp
- Rwa Wealth Partners
- Everett Harris & Co ca/
- Saturna Capital Corp
- Capital International, ca/
- Avoro Capital Advisors